Adil I Daud (Adil Daud)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 25

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

American journal of clinical dermatology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer immunology research

University of California, San Francisco

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of California, San Francisco Jun 06 2008

United States

professor :: medicine

Publications

Alexandra Haugh, Adil I Daud
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. American journal of clinical dermatology 25 (3) (2024)
Alexandra Haugh, Adil I Daud
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. American journal of clinical dermatology (2024)
Alexandra Haugh, Adil I Daud
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. American journal of clinical dermatology 25 (3) (2024)
Alexandra Haugh, Adil I Daud
Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I? Cancer immunology research (2023)
Valentin Feichtenschlager, Linan Chen, Yixuan James Zheng, Wilson Ho, Martina Sanlorenzo, Igor Vujic, Eleanor Fewings, Albert Lee, Christopher Chen, Ciara Callanan, Kevin Lin, Tiange Qu, Dasha Hohlova, Marin Vujic, Y Christina Hwang, Kevin Lai, Stephanie Chen, Thuan Nguyen, Denise P Muñoz, Yoshinori Kohwi, Christian Posch, Adil I Daud, Klemens Rappersberger, Terumi Kohwi-Shigematsu, Jean-Philippe Coppé, Susana Ortiz-Urda
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma. Research square (2023)
Filippo de Braud, Christophe Dooms, Rebecca S Heist, Celeste Lebbè, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Lukasz Rutkowski, Juergen Wolf, Paolo Antonio Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith A McKean, Eva Muñoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuân-Mai Couillebault, Helen Evans, Catarina D Campbell, Sumit Basu, Michele Moschetta, Adil I Daud
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Caroline Robert, Matteo S Carlino, Catriona McNeil, Antoni Ribas, Jean-Jacques Grob, Jacob Schachter, Marta Nyakas, Damien Kee, Teresa M Petrella, Arnold Blaustein, Michal Lotem, Ana Arance, Adil I Daud, Omid Hamid, James M G Larkin, James Anderson, Clemens Krepler, Dmitri Grebennik, Georgina V Long
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Laura A Huppert, Adil I Daud
Intratumoral therapies and in-situ vaccination for melanoma. Human vaccines & immunotherapeutics 18 (3) (2022)
Mia Han, Bianca Nguyen, Jack Y Lee, Erica Browning, Jun Zhang, Anandaroop Mukhopadhyay, Ravindra Gujar, Jon Salazar, Reneta Hermiz, Lauren Svenson, Annah S Rolig, William L Redmond, Alain Patrick Algazi, Adil I Daud, David A Canton, Christopher G Twitty
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity. Molecular cancer research : MCR 20 (6) (2022)
Laura A Huppert, Adil I Daud
Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (24) (2021)
Michael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, Susan M Swetter, Hensin Tsao, Julio A Aguirre-Ghiso, Maria S Soengas, Ashani T Weeraratna, Keith T Flaherty, Meenhard Herlyn, Jeffrey A Sosman, Hussein A Tawbi, Anna C Pavlick, Pamela B Cassidy, Sunandana Chandra, Paul B Chapman, Adil I Daud, Zeynep Eroglu, Laura K Ferris, Bernard A Fox, Jeffrey E Gershenwald, Geoffrey T Gibney, Douglas Grossman, Brent A Hanks, Douglas Hanniford, Eva Hernando, Joanne M Jeter, Douglas B Johnson, Samir N Khleif, John M Kirkwood, Sancy A Leachman, Darren Mays, Kelly C Nelson, Vernon K Sondak, Ryan J Sullivan, Glenn Merlino, null null
The State of Melanoma: Emergent Challenges and Opportunities. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Pooja Mehta, Victoire Gouirand, Devi P Boda, Jingxian Zhang, Sofia V Gearty, Bahar Zirak, Margaret M Lowe, Sean Clancy, Ian C Boothby, Kelly M Mahuron, Adam Fries, Matthew F Krummel, Parminder Mankoo, Hsin-Wen Chang, Jared Liu, Joshua M Moreau, Tiffany C Scharschmidt, Adil I Daud, Esther Kim, Isaac M Neuhaus, Hobart W Harris, Wilson Liao, Michael D Rosenblum
Layilin Anchors Regulatory T Cells in Skin. Journal of immunology (Baltimore, Md. : 1950) 207 (7) (2021)
James C Lee, Michael D Green, Laura A Huppert, Christine Chow, Robert H Pierce, Adil I Daud
The Liver-Immunity Nexus and Cancer Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
James C Lee, Sadaf Mehdizadeh, Jennifer A Smith, Arabella Young, Ilgiz A Mufazalov, Cody T Mowery, Adil I Daud, Jeffrey A Bluestone
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Science immunology 5 (52) (2021)
Alain Patrick Algazi, Megan K D Othus, Adil I Daud, Roger S Lo, Janice M Mehnert, Thach-Giao Truong, Robert Conry, Kari Kendra, Gary C Doolittle, Joseph I Clark, Michael J Messino, Dennis F Moore, Christopher Lao, Bryan A Faller, Rangaswamy Govindarajan, Amy Harker-Murray, Luke Dreisbach, James Moon, Kenneth F Grossmann, Antoni Ribas
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature medicine 26 (10) (2020)
Lauren S Levine, Kelly M Mahuron, Katy K Tsai, Clinton Wu, Daiva M Mattis, Mariela L Pauli, Arielle Oglesby, James C Lee, Matthew H Spitzer, Matthew F Krummel, Alain P Algazi, Michael D Rosenblum, Michael Alvarado, Adil I Daud
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Annals of surgical oncology 27 (11) (2020)
Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark M Moasser, Amy J Chien, Michelle E Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil I Daud, Michael D Rosenblum, Scott Thomas, Pamela N Munster
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nature communications 11 (1) (2020)
Kelly M Mahuron, Lauren S Levine, Adil I Daud
ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Annals of surgical oncology 27 (11) (2020)
Antoni Ribas, Adil I Daud, Anna C Pavlick, Rene Gonzalez, Karl D Lewis, Omid Hamid, Thomas F Gajewski, Igor Puzanov, Matthew J Wongchenko, Isabelle Rooney, Jessie J Hsu, Yibing Yan, Erica Park, Grant A McArthur
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (1) (2019)
Shailender Bhatia, Natalie V Longino, Natalie J Miller, Rima Kulikauskas, Jayasri G Iyer, Dafina Ibrani, Astrid Blom, David R Byrd, Upendra Parvathaneni, Christopher G Twitty, Jean S Campbell, Mai H Le, Sharron Gargosky, Robert H Pierce, Richard Heller, Adil I Daud, Paul T Nghiem
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (3) (2019)
Samantha K Greaney, Alain P Algazi, Katy K Tsai, Kathryn T Takamura, Lawrence Chen, Christopher G Twitty, Li Zhang, Alan Paciorek, Robert H Pierce, Mai H Le, Adil I Daud, Lawrence Fong
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer immunology research 8 (2) (2019)
Johannes G Reiter, Nilofer S Azad, Jeffrey M Gerold, Alvin P Makohon-Moore, Adil I Daud, Christine A Iacobuzio-Donahue, Nilofer S Azad, Kenneth W Kinzler, Martin A Nowak, Bert Vogelstein
An analysis of genetic heterogeneity in untreated cancers. Nature reviews. Cancer 19 (11) (2019)
Kevin C Barry, Joy Hsu, Miranda L Broz, Francisco J Cueto, Mikhail Binnewies, Alexis J Combes, Amanda E Nelson, Kimberly Loo, Raj Kumar, Michael D Rosenblum, Michael D Alvarado, Denise M Wolf, Dusan Bogunovic, Nina Bhardwaj, Adil I Daud, Patrick K Ha, William R Ryan, Joshua L Pollack, Bushra Samad, Saurabh Asthana, Vincent Chan, Matthew F Krummel
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nature medicine 24 (8) (2018)
Martina Sanlorenzo, Igor Vujic, Rosaura Esteve-Puig, Kevin Lai, Marin Vujic, Kevin Lin, Christian Posch, Michelle Dimon, Adrian Moy, Mitchell Zekhtser, Katia Johnston, Deborah Gho, Wilson Ho, Abhinay Gajjala, Juan A Oses-Prieto, Alma Burlingame, Adil I Daud, Klemens Rappersberger, Susana Ortiz-Urda
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Scientific reports 8 (1) (2018)
Douglas B Johnson, Jennifer Bordeaux, Ju Young Kim, Christine Vaupel, David L Rimm, Thai H Ho, Richard W Joseph, Adil I Daud, Robert M Conry, Elizabeth M Gaughan, Leonel F Hernandez-Aya, Anastasios Dimou, Pauline Funchain, James W Smithy, John S Witte, Svetlana B McKee, Jennifer Susan Ko, Justin M Balko, Bashar Dabbas, Shabnam Tangri, Jelveh Lameh, Jeffrey Hall, Joseph Markowitz, Naveen Dakappagari
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (21) (2018)

Adil I Daud.css-eqlu8i{font-size:small;padding-left:4px;} (Adil Daud)

Publication Activity (10 Years)

Top Topics

Top Venues

Adil I Daud (Adil Daud)